@article{3104104,
    title = "Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia",
    author = "Filippidou, M. and Avgerinou, G. and Tsipou, H. and Tourkantoni, N. and Katsibardi, K. and Vlachou, A. and Roka, K. and Solomou, E. and Kattamis, A.",
    journal = "British Journal of Haematology",
    year = "2020",
    volume = "190",
    number = "3",
    pages = "e157-e159",
    publisher = "Wiley-Blackwell Publishing Ltd",
    issn = "0007-1048, 1365-2141",
    doi = "10.1111/bjh.16766",
    keywords = "cyclosporine;  eltrombopag;  thymocyte antibody;  benzoic acid;  cyclosporine;  eltrombopag;  hydrazine derivative;  immunosuppressive agent;  lymphocyte antibody;  MPL protein, human;  pyrazole derivative;  thrombopoietin receptor, adolescent;  aplastic anemia;  child;  chronic kidney failure;  clinical article;  death;  drug efficacy;  drug response;  drug safety;  drug tolerability;  female;  follow up;  hematopoietic stem cell transplantation;  human;  immunosuppressive treatment;  Letter;  longitudinal study;  low drug dose;  male;  matched unrelated donor;  preschool child;  priority journal;  relapse;  school child;  thrombocytopenia;  treatment duration;  treatment outcome;  virus encephalitis;  aplastic anemia;  clinical trial;  off label drug use, Adolescent;  Anemia, Aplastic;  Antilymphocyte Serum;  Benzoates;  Child;  Child, Preschool;  Cyclosporine;  Female;  Follow-Up Studies;  Humans;  Hydrazines;  Immunosuppressive Agents;  Male;  Off-Label Use;  Pyrazoles;  Receptors, Thrombopoietin;  Treatment Outcome"
}